Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

M. Herman Chui¹, Susanne K. Kjaer^3,4, Kirsten Frederiksen³, Charlotte G. Hannibal³, Tian-Li Wang¹, Russell Vang^1,2,* and Ie-Ming Shih^1,2,*

¹ Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
² Department of Obstetrics & Gynecology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
³ Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
⁴ Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark
^* These authors have contributed equally to this work

Published: June 22, 2021

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:6870–6878. DOI: https://doi.org/10.18632/oncotarget.27326.